E-viri
Recenzirano
Odprti dostop
-
Smith, B. Douglas; DeZern, Amy E.; Bastian, Alex W.; Durie, Brian G. M.
Cancer, May 15, 2017, Letnik: 123, Številka: 10Journal Article
BACKGROUND Overall survival (OS) is considered the gold standard for determining treatment efficacy in oncology trials, but the relation between treatment and OS can be challenging to assess because of long study durations and the impact of subsequent therapies on outcome. Using OS can be particularly difficult for new therapies in hematologic malignancies (HMs). METHODS This retrospective analysis was conducted to characterize the primary endpoints used to support US Food and Drug Administration (FDA) approvals for new drug or novel HM indications between January 2002 and July 2015. Data on approvals were retrieved from the FDA and CenterWatch websites, and from the FDA prescribing information on respective products at the time of approval. RESULTS Sixty‐three FDA approvals involving 35 drugs and 16 HMs were identified. Of the 63 approvals, 45 (71.4%) included response rate (RR), and 17 (27%) included progression‐free survival (PFS; n = 14) or time to progression (n = 3), and 1 approval included OS. Twenty‐three approvals (36.5%) included trials with an active comparator arm. The median relative magnitude of benefit versus comparator was 71% improvement (range, 26%‐127%), with a median hazard ratio of 0.55 (range, 0.16‐0.72). CONCLUSIONS FDA approvals for new drug or novel HM indications are often based on endpoints other than OS, such as RR and PFS. Tools for determining the magnitude of clinical benefit and treatment value in HMs should take into account the importance of RR, PFS, and other non‐OS endpoints. Cancer 2017;123:1689–1694. © 2017 American Cancer Society. This retrospective review indicates that US Food and Drug Administration approvals of treatments for hematologic malignancies often include endpoints other than overall survival, such as progression‐free survival and response rate. Effective assessment of the value of treatment options should be made with a clear understanding of appropriate outcomes for hematologic malignancies and realistic expectations regarding the nature and magnitude of meaningful benefit.
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.